{"transactions":[{"id":726366,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":15980,"kind":"person","name":"Lynch Thomas J. Jr.","position":1,"cik":"0001474056","reported_name":"Lynch Thomas J. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:06:54.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001474056-26-000007","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474056/000147405626000007/primarydocument.xml","form_type":"4"}},{"id":726138,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35319,"kind":"person","name":"Duty Stuart","position":1,"cik":"0001970274","reported_name":"Duty Stuart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:06:03.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001970274-26-000007","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000197027426000007/primarydocument.xml","form_type":"4"}},{"id":726182,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:05:13.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001581956-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000158195626000004/primarydocument.xml","form_type":"4"}},{"id":726669,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:04:20.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001972849-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000197284926000004/primarydocument.xml","form_type":"4"}},{"id":726181,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35327,"kind":"person","name":"Mendelsohn Michael","position":1,"cik":"0001591109","reported_name":"Mendelsohn Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:03:35.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001591109-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591109/000159110926000004/primarydocument.xml","form_type":"4"}},{"id":726255,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":16070,"kind":"person","name":"SMITH IAN F","position":1,"cik":"0001197032","reported_name":"SMITH IAN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:02:49.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001197032-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197032/000119703226000005/primarydocument.xml","form_type":"4"}},{"id":726637,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35426,"kind":"person","name":"GILL SIMBA","position":1,"cik":"0001180763","reported_name":"GILL SIMBA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:01:48.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001180763-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180763/000118076326000005/primarydocument.xml","form_type":"4"}},{"id":726900,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":18114,"kind":"person","name":"PARSHALL B LYNNE","position":1,"cik":"0001073385","reported_name":"PARSHALL B LYNNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:01:18.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001073385-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1073385/000107338526000004/primarydocument.xml","form_type":"4"}},{"id":726374,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:00:41.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001486373-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000148637326000005/primarydocument.xml","form_type":"4"}},{"id":809421,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T20:01:20.000Z","date":"2026-04-10","kind":"gift","planned":false,"acquired":true,"shares":59208,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Living Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 10, 2026, the Adrian H. Gottschalk 2025 Grantor Retained Annuity Trust dated April 25, 2025, of which the Reporting Person is the trustee and sole current beneficiary (the \"2025 GRAT\"), distributed 59,208 shares of the Issuer's Common Stock to the Living Trust."}],"balance_after":270912,"source":{"system":"sec-edgar","filing":"0001828724-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000182872426000005/primarydocument.xml","form_type":"4"}},{"id":809420,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T20:01:20.000Z","date":"2026-04-10","kind":"gift","planned":false,"acquired":false,"shares":59208,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"2025 GRAT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 10, 2026, the Adrian H. Gottschalk 2025 Grantor Retained Annuity Trust dated April 25, 2025, of which the Reporting Person is the trustee and sole current beneficiary (the \"2025 GRAT\"), distributed 59,208 shares of the Issuer's Common Stock to the Living Trust."}],"balance_after":240792,"source":{"system":"sec-edgar","filing":"0001828724-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000182872426000005/primarydocument.xml","form_type":"4"}},{"id":809419,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T20:01:20.000Z","date":"2026-04-09","kind":"gift","planned":false,"acquired":true,"shares":47497,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Living Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 9, 2026, the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023, of which the Reporting Person is the trustee and sole current beneficiary (the \"2023 GRAT\"), distributed 47,497 shares of the Issuer's Common Stock to the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee (the \"Living Trust\")."}],"balance_after":211704,"source":{"system":"sec-edgar","filing":"0001828724-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000182872426000005/primarydocument.xml","form_type":"4"}},{"id":809418,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T20:01:20.000Z","date":"2026-04-09","kind":"gift","planned":false,"acquired":false,"shares":47497,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 2023 GRAT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 9, 2026, the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023, of which the Reporting Person is the trustee and sole current beneficiary (the \"2023 GRAT\"), distributed 47,497 shares of the Issuer's Common Stock to the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee (the \"Living Trust\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001828724-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000182872426000005/primarydocument.xml","form_type":"4"}},{"id":884309,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":36777,"kind":"person","name":"Maynard Ryan D","position":1,"cik":"0001363984","reported_name":"Maynard Ryan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-24T21:02:39.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":5.75,"value":2300000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on February 23, 2027, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested."}],"balance_after":400000,"derivative":{"exercise_price":5.75,"expiration_date":"2036-02-22","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001363984-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363984/000136398426000004/primarydocument.xml","form_type":"4"}},{"id":915650,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-02-06T21:01:11.000Z","date":"2026-02-05","kind":"grant","planned":false,"acquired":true,"shares":1075000,"price":5.23,"value":5622250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on February 5, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":1075000,"derivative":{"exercise_price":5.23,"expiration_date":"2036-02-04","underlying":"Common Stock","underlying_shares":1075000},"source":{"system":"sec-edgar","filing":"0001828724-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000182872426000003/primarydocument.xml","form_type":"4"}},{"id":924403,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-02-02T21:04:42.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":230000,"price":5.71,"value":1313300.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":230000,"derivative":{"exercise_price":5.71,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001939167-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000193916726000002/primarydocument.xml","form_type":"4"}},{"id":924402,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68154,"kind":"person","name":"LaCascia Michael","position":1,"cik":"0001831755","reported_name":"LaCascia Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-02-02T21:03:48.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":295000,"price":5.71,"value":1684450.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":295000,"derivative":{"exercise_price":5.71,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":295000},"source":{"system":"sec-edgar","filing":"0001831755-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000183175526000002/primarydocument.xml","form_type":"4"}},{"id":924401,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68153,"kind":"person","name":"Bellon Steven F.","position":1,"cik":"0001831749","reported_name":"Bellon Steven F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-02T21:01:11.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":5.71,"value":1713000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":300000,"derivative":{"exercise_price":5.71,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001831749-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000183174926000002/primarydocument.xml","form_type":"4"}},{"id":924449,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68157,"kind":"person","name":"Cardama Alfonso Quintas","position":1,"cik":"0001760104","reported_name":"Cardama Alfonso Quintas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-02-02T16:03:02.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":5.71,"value":1713000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":300000,"derivative":{"exercise_price":5.71,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001760104-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760104/000176010426000002/primarydocument.xml","form_type":"4"}},{"id":925551,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68237,"kind":"person","name":"Rivkin Anna","position":1,"cik":"0002035647","reported_name":"Rivkin Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-02-02T16:02:22.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":165000,"price":5.71,"value":942150.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":165000,"derivative":{"exercise_price":5.71,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0002035647-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035647/000203564726000002/primarydocument.xml","form_type":"4"}},{"id":938821,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":63978,"kind":"organization","name":"Flagship Pioneering, LLC","position":1,"cik":"0001400240","reported_name":"Flagship Pioneering, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63981,"kind":"organization","name":"Flagship Pioneering Fund VII General Partner LLC","position":2,"cik":"0001805917","reported_name":"Flagship Pioneering Fund VII General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64112,"kind":"organization","name":"Flagship Pioneering Fund VII, L.P.","position":3,"cik":"0001805916","reported_name":"Flagship Pioneering Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63983,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","position":4,"cik":"0001826217","reported_name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64114,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II, L.P.","position":5,"cik":"0001761283","reported_name":"Flagship Pioneering Special Opportunities Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69363,"kind":"person","name":"Flagship Ventures Fund V General Partner LLC","position":6,"cik":"0001724575","reported_name":"Flagship Ventures Fund V General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69364,"kind":"person","name":"Flagship Ventures Fund V, L.P.","position":7,"cik":"0001627639","reported_name":"Flagship Ventures Fund V, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69365,"kind":"person","name":"Flagship Ventures Opportunities Fund I General Partner LLC","position":8,"cik":"0001725004","reported_name":"Flagship Ventures Opportunities Fund I General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69366,"kind":"person","name":"Flagship Ventures Opportunities Fund I, L.P.","position":9,"cik":"0001677345","reported_name":"Flagship Ventures Opportunities Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44731,"kind":"person","name":"Afeyan Noubar","position":10,"cik":"0001222012","reported_name":"AFEYAN NOUBAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 2 Warrants to purchase Common Stock","published_at":"2026-01-15T17:00:05.000Z","date":"2026-01-13","kind":"grant","planned":false,"acquired":true,"shares":1117734,"ownership":{"direct":false,"nature":"By Flagship Pioneering Fund VII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the \"Weighted-Average Price\") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. (\"Flagship Fund VII\") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the \"Series Warrants\"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC (\"Flagship Fund VII GP\") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., \"Flagship Pioneering\") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1117734,"derivative":{"exercise_price":20.13,"exercise_date":"2026-01-13","expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":1117734},"source":{"system":"sec-edgar","filing":"0001193125-26-014218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805916/000119312526014218/ownership.xml","form_type":"4"}},{"id":938820,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":63978,"kind":"organization","name":"Flagship Pioneering, LLC","position":1,"cik":"0001400240","reported_name":"Flagship Pioneering, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63981,"kind":"organization","name":"Flagship Pioneering Fund VII General Partner LLC","position":2,"cik":"0001805917","reported_name":"Flagship Pioneering Fund VII General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64112,"kind":"organization","name":"Flagship Pioneering Fund VII, L.P.","position":3,"cik":"0001805916","reported_name":"Flagship Pioneering Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63983,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","position":4,"cik":"0001826217","reported_name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64114,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II, L.P.","position":5,"cik":"0001761283","reported_name":"Flagship Pioneering Special Opportunities Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69363,"kind":"person","name":"Flagship Ventures Fund V General Partner LLC","position":6,"cik":"0001724575","reported_name":"Flagship Ventures Fund V General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69364,"kind":"person","name":"Flagship Ventures Fund V, L.P.","position":7,"cik":"0001627639","reported_name":"Flagship Ventures Fund V, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69365,"kind":"person","name":"Flagship Ventures Opportunities Fund I General Partner LLC","position":8,"cik":"0001725004","reported_name":"Flagship Ventures Opportunities Fund I General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69366,"kind":"person","name":"Flagship Ventures Opportunities Fund I, L.P.","position":9,"cik":"0001677345","reported_name":"Flagship Ventures Opportunities Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44731,"kind":"person","name":"Afeyan Noubar","position":10,"cik":"0001222012","reported_name":"AFEYAN NOUBAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Warrants to purchase Common Stock","published_at":"2026-01-15T17:00:05.000Z","date":"2026-01-13","kind":"grant","planned":false,"acquired":true,"shares":1117734,"ownership":{"direct":false,"nature":"By Flagship Pioneering Fund VII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the \"Weighted-Average Price\") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. (\"Flagship Fund VII\") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the \"Series Warrants\"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC (\"Flagship Fund VII GP\") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., \"Flagship Pioneering\") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1117734,"derivative":{"exercise_price":13.42,"exercise_date":"2026-01-13","expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":1117734},"source":{"system":"sec-edgar","filing":"0001193125-26-014218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805916/000119312526014218/ownership.xml","form_type":"4"}},{"id":938819,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":63978,"kind":"organization","name":"Flagship Pioneering, LLC","position":1,"cik":"0001400240","reported_name":"Flagship Pioneering, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63981,"kind":"organization","name":"Flagship Pioneering Fund VII General Partner LLC","position":2,"cik":"0001805917","reported_name":"Flagship Pioneering Fund VII General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64112,"kind":"organization","name":"Flagship Pioneering Fund VII, L.P.","position":3,"cik":"0001805916","reported_name":"Flagship Pioneering Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63983,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","position":4,"cik":"0001826217","reported_name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64114,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II, L.P.","position":5,"cik":"0001761283","reported_name":"Flagship Pioneering Special Opportunities Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69363,"kind":"person","name":"Flagship Ventures Fund V General Partner LLC","position":6,"cik":"0001724575","reported_name":"Flagship Ventures Fund V General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69364,"kind":"person","name":"Flagship Ventures Fund V, L.P.","position":7,"cik":"0001627639","reported_name":"Flagship Ventures Fund V, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69365,"kind":"person","name":"Flagship Ventures Opportunities Fund I General Partner LLC","position":8,"cik":"0001725004","reported_name":"Flagship Ventures Opportunities Fund I General Partner LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69366,"kind":"person","name":"Flagship Ventures Opportunities Fund I, L.P.","position":9,"cik":"0001677345","reported_name":"Flagship Ventures Opportunities Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44731,"kind":"person","name":"Afeyan Noubar","position":10,"cik":"0001222012","reported_name":"AFEYAN NOUBAR","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase Common Stock","published_at":"2026-01-15T17:00:05.000Z","date":"2026-01-13","kind":"grant","planned":false,"acquired":true,"shares":2235468,"price":6.7099,"value":14999766.7332,"ownership":{"direct":false,"nature":"By Flagship Pioneering Fund VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. (\"Flagship Fund VII\") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the \"Series Warrants\"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC (\"Flagship Fund VII GP\") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., \"Flagship Pioneering\") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":2235468,"derivative":{"exercise_price":0.0001,"exercise_date":"2026-01-13","expiration_date":"2046-01-13","underlying":"Common Stock","underlying_shares":2235468},"source":{"system":"sec-edgar","filing":"0001193125-26-014218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805916/000119312526014218/ownership.xml","form_type":"4"}},{"id":1107709,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":16070,"kind":"person","name":"SMITH IAN F","position":1,"cik":"0001197032","reported_name":"SMITH IAN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:29:40.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":4.79,"value":119750.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":4.79,"exercise_date":"2026-06-17","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-25-004909","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197032/000156218025004909/primarydocument.xml","form_type":"4"}},{"id":1108691,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":18114,"kind":"person","name":"PARSHALL B LYNNE","position":1,"cik":"0001073385","reported_name":"PARSHALL B LYNNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:29:16.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":4.79,"value":119750.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":4.79,"exercise_date":"2026-06-17","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-25-004908","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1073385/000156218025004908/primarydocument.xml","form_type":"4"}},{"id":1107526,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35327,"kind":"person","name":"Mendelsohn Michael","position":1,"cik":"0001591109","reported_name":"Mendelsohn Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:28:43.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":4.79,"value":119750.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":4.79,"exercise_date":"2026-06-17","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-25-004907","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591109/000156218025004907/primarydocument.xml","form_type":"4"}},{"id":1107878,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":15980,"kind":"person","name":"Lynch Thomas J. Jr.","position":1,"cik":"0001474056","reported_name":"Lynch Thomas J. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:28:10.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":4.79,"value":119750.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":4.79,"exercise_date":"2026-06-17","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-25-004906","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474056/000156218025004906/primarydocument.xml","form_type":"4"}},{"id":1108249,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35426,"kind":"person","name":"GILL SIMBA","position":1,"cik":"0001180763","reported_name":"GILL SIMBA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:27:20.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":4.79,"value":119750.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":4.79,"exercise_date":"2026-06-17","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-25-004902","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180763/000156218025004902/primarydocument.xml","form_type":"4"}},{"id":1107542,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:26:56.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":4.79,"value":119750.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":4.79,"exercise_date":"2026-06-17","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-25-004899","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000156218025004899/primarydocument.xml","form_type":"4"}},{"id":1107913,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:25:41.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":4.79,"value":119750.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":4.79,"exercise_date":"2026-06-17","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-25-004893","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218025004893/primarydocument.xml","form_type":"4"}},{"id":1161352,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-05-02T20:04:44.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":4.16,"value":208000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to one-third of the underlying shares of common stock on each of the first three anniversaries of the date of grant, subject to the recipient's continuing service on the board of directors."}],"balance_after":50000,"derivative":{"exercise_price":4.16,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-25-003475","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000156218025003475/primarydocument.xml","form_type":"4"}},{"id":1160689,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35319,"kind":"person","name":"Duty Stuart","position":1,"cik":"0001970274","reported_name":"Duty Stuart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-05-02T20:03:21.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":4.16,"value":208000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to one-third of the underlying shares of common stock on each of the first three anniversaries of the date of grant, subject to the recipient's continuing service on the board of directors."}],"balance_after":50000,"derivative":{"exercise_price":4.16,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-25-003474","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218025003474/primarydocument.xml","form_type":"4"}},{"id":1164733,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-28T20:01:58.000Z","date":"2025-04-25","kind":"gift","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 25, 2025, the Adrian H. Gottschalk Living Trust dated September 8, 2009 (the \"Gottschalk Living Trust\"), of which the Reporting Person is the trustee, distributed 300,000 shares of the Issuer's Common Stock to the Adrian H. Gottschalk 2025 Grantor Retained Annuity Trust dated April 25, 2025 (the \"Gottschalk 2025 GRAT\"), of which the Reporting Person is the trustee and sole current beneficiary."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 47,497 shares held by the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023, 300,000 shares held by the Gottschalk 2025 GRAT, and 164,207 shares held by the Gottschalk Living Trust."}],"balance_after":511704,"source":{"system":"sec-edgar","filing":"0001562180-25-003257","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218025003257/primarydocument.xml","form_type":"4"}},{"id":1164732,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-28T20:01:58.000Z","date":"2025-04-25","kind":"gift","planned":false,"acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 25, 2025, the Adrian H. Gottschalk Living Trust dated September 8, 2009 (the \"Gottschalk Living Trust\"), of which the Reporting Person is the trustee, distributed 300,000 shares of the Issuer's Common Stock to the Adrian H. Gottschalk 2025 Grantor Retained Annuity Trust dated April 25, 2025 (the \"Gottschalk 2025 GRAT\"), of which the Reporting Person is the trustee and sole current beneficiary."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 47,497 shares held by the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023, 300,000 shares held by the Gottschalk 2025 GRAT, and 164,207 shares held by the Gottschalk Living Trust."}],"balance_after":511704,"source":{"system":"sec-edgar","filing":"0001562180-25-003257","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218025003257/primarydocument.xml","form_type":"4"}},{"id":1173792,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-10T20:01:26.000Z","date":"2025-04-09","kind":"gift","planned":false,"acquired":true,"shares":197906,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 9, 2025, the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023, of which the Reporting Person is the trustee and sole current beneficiary (the \"Gottschalk 2023 GRAT\"), distributed 197,906 shares of the Issuer's Common Stock to the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee (the \"Gottschalk Living Trust\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 47,497 shares held by the Gottschalk 2023 GRAT and 464,207 shares held by the Gottschalk Living Trust."}],"balance_after":511704,"source":{"system":"sec-edgar","filing":"0001562180-25-003092","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218025003092/primarydocument.xml","form_type":"4"}},{"id":1173791,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-10T20:01:26.000Z","date":"2025-04-09","kind":"gift","planned":false,"acquired":false,"shares":197906,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 9, 2025, the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023, of which the Reporting Person is the trustee and sole current beneficiary (the \"Gottschalk 2023 GRAT\"), distributed 197,906 shares of the Issuer's Common Stock to the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee (the \"Gottschalk Living Trust\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 47,497 shares held by the Gottschalk 2023 GRAT and 464,207 shares held by the Gottschalk Living Trust."}],"balance_after":511704,"source":{"system":"sec-edgar","filing":"0001562180-25-003092","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218025003092/primarydocument.xml","form_type":"4"}},{"id":1295291,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-24T21:13:52.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":4.37,"value":502550.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":115000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001562180-25-000504","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218025000504/primarydocument.xml","form_type":"4"}},{"id":1295290,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-24T21:10:43.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":4.37,"value":1748000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":400000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001562180-25-000501","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218025000501/primarydocument.xml","form_type":"4"}},{"id":1295289,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68153,"kind":"person","name":"Bellon Steven F.","position":1,"cik":"0001831749","reported_name":"Bellon Steven F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-24T21:09:02.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":4.37,"value":611800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":140000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001562180-25-000500","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218025000500/primarydocument.xml","form_type":"4"}},{"id":1295288,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68154,"kind":"person","name":"LaCascia Michael","position":1,"cik":"0001831755","reported_name":"LaCascia Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-24T21:06:45.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":126000,"price":4.37,"value":550620.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":126000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":126000},"source":{"system":"sec-edgar","filing":"0001562180-25-000499","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218025000499/primarydocument.xml","form_type":"4"}},{"id":1295303,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68157,"kind":"person","name":"Cardama Alfonso Quintas","position":1,"cik":"0001760104","reported_name":"Cardama Alfonso Quintas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-24T16:16:18.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":4.37,"value":546250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":125000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001562180-25-000506","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760104/000156218025000506/primarydocument.xml","form_type":"4"}},{"id":1295692,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":71808,"kind":"person","name":"Humer Kristian","position":1,"cik":"0001872280","reported_name":"Humer Kristian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-24T16:15:38.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":4.37,"value":524400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":120000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001562180-25-000505","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872280/000156218025000505/primarydocument.xml","form_type":"4"}},{"id":1295760,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68237,"kind":"person","name":"Rivkin Anna","position":1,"cik":"0002035647","reported_name":"Rivkin Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-24T16:11:43.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":4.37,"value":218500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":50000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-25-000502","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035647/000156218025000502/primarydocument.xml","form_type":"4"}},{"id":1399855,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-24T20:01:55.000Z","date":"2024-09-23","kind":"exercise","planned":true,"acquired":false,"shares":857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested."}],"balance_after":39789,"derivative":{"exercise_price":3.72,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":857},"source":{"system":"sec-edgar","filing":"0001562180-24-006927","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006927/primarydocument.xml","form_type":"4"}},{"id":1399854,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-24T20:01:55.000Z","date":"2024-09-20","kind":"exercise","planned":true,"acquired":false,"shares":35756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested."}],"balance_after":40646,"derivative":{"exercise_price":3.72,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":35756},"source":{"system":"sec-edgar","filing":"0001562180-24-006927","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006927/primarydocument.xml","form_type":"4"}},{"id":1399853,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-24T20:01:55.000Z","date":"2024-09-23","kind":"sale","planned":true,"acquired":false,"shares":857,"price":10.17,"value":8715.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-24-006927","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006927/primarydocument.xml","form_type":"4"}},{"id":1399852,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-24T20:01:55.000Z","date":"2024-09-23","kind":"exercise","planned":true,"acquired":true,"shares":857,"price":3.72,"value":3188.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."}],"balance_after":857,"source":{"system":"sec-edgar","filing":"0001562180-24-006927","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006927/primarydocument.xml","form_type":"4"}},{"id":1399851,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-24T20:01:55.000Z","date":"2024-09-20","kind":"sale","planned":true,"acquired":false,"shares":35756,"price":10.04,"value":358990.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.22 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-24-006927","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006927/primarydocument.xml","form_type":"4"}},{"id":1399850,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-24T20:01:55.000Z","date":"2024-09-20","kind":"exercise","planned":true,"acquired":true,"shares":35756,"price":3.72,"value":133012.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."}],"balance_after":35756,"source":{"system":"sec-edgar","filing":"0001562180-24-006927","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006927/primarydocument.xml","form_type":"4"}},{"id":1401341,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-20T20:00:59.000Z","date":"2024-09-18","kind":"exercise","planned":true,"acquired":false,"shares":11574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested."}],"balance_after":76402,"derivative":{"exercise_price":3.72,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":11574},"source":{"system":"sec-edgar","filing":"0001562180-24-006885","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006885/primarydocument.xml","form_type":"4"}},{"id":1401340,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-20T20:00:59.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":11574,"price":10.05,"value":116318.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.25 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-24-006885","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006885/primarydocument.xml","form_type":"4"}},{"id":1401339,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-20T20:00:59.000Z","date":"2024-09-18","kind":"exercise","planned":true,"acquired":true,"shares":11574,"price":3.72,"value":43055.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."}],"balance_after":11574,"source":{"system":"sec-edgar","filing":"0001562180-24-006885","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006885/primarydocument.xml","form_type":"4"}},{"id":1403079,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-18T20:01:22.000Z","date":"2024-09-17","kind":"exercise","planned":true,"acquired":false,"shares":10272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested."}],"balance_after":87976,"derivative":{"exercise_price":3.72,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":10272},"source":{"system":"sec-edgar","filing":"0001562180-24-006859","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006859/primarydocument.xml","form_type":"4"}},{"id":1403078,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-18T20:01:22.000Z","date":"2024-09-16","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested."}],"balance_after":98248,"derivative":{"exercise_price":3.72,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001562180-24-006859","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006859/primarydocument.xml","form_type":"4"}},{"id":1403077,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-18T20:01:22.000Z","date":"2024-09-17","kind":"sale","planned":true,"acquired":false,"shares":10272,"price":10.04,"value":103130.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.18 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-24-006859","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006859/primarydocument.xml","form_type":"4"}},{"id":1403076,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-18T20:01:22.000Z","date":"2024-09-17","kind":"exercise","planned":true,"acquired":true,"shares":10272,"price":3.72,"value":38211.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."}],"balance_after":10272,"source":{"system":"sec-edgar","filing":"0001562180-24-006859","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006859/primarydocument.xml","form_type":"4"}},{"id":1403075,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-18T20:01:22.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":400,"price":10,"value":4000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-24-006859","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006859/primarydocument.xml","form_type":"4"}},{"id":1403074,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2024-09-18T20:01:22.000Z","date":"2024-09-16","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":3.72,"value":1488.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."}],"balance_after":400,"source":{"system":"sec-edgar","filing":"0001562180-24-006859","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006859/primarydocument.xml","form_type":"4"}},{"id":1409369,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68153,"kind":"person","name":"Bellon Steven F.","position":1,"cik":"0001831749","reported_name":"Bellon Steven F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-09-11T20:00:27.000Z","date":"2024-09-09","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":9.5,"value":190000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024."}],"balance_after":101957,"source":{"system":"sec-edgar","filing":"0001562180-24-006767","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024006767/primarydocument.xml","form_type":"4"}},{"id":1416237,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68237,"kind":"person","name":"Rivkin Anna","position":1,"cik":"0002035647","reported_name":"Rivkin Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2024-09-04T16:02:47.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":7.85,"value":1491500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on September 3, 2025, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested."}],"balance_after":190000,"derivative":{"exercise_price":7.85,"expiration_date":"2034-09-03","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001562180-24-006632","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035647/000156218024006632/primarydocument.xml","form_type":"4"}},{"id":1467007,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:08:04.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005363","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000156218024005363/primarydocument.xml","form_type":"4"}},{"id":1466995,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35327,"kind":"person","name":"Mendelsohn Michael","position":1,"cik":"0001591109","reported_name":"Mendelsohn Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:07:38.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005362","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591109/000156218024005362/primarydocument.xml","form_type":"4"}},{"id":1467076,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":16070,"kind":"person","name":"SMITH IAN F","position":1,"cik":"0001197032","reported_name":"SMITH IAN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:06:35.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005361","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197032/000156218024005361/primarydocument.xml","form_type":"4"}},{"id":1467165,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":15980,"kind":"person","name":"Lynch Thomas J. Jr.","position":1,"cik":"0001474056","reported_name":"Lynch Thomas J. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:06:10.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005360","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474056/000156218024005360/primarydocument.xml","form_type":"4"}},{"id":1467353,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35426,"kind":"person","name":"GILL SIMBA","position":1,"cik":"0001180763","reported_name":"GILL SIMBA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:04:41.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005359","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180763/000156218024005359/primarydocument.xml","form_type":"4"}},{"id":1467172,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:03:47.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005358","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218024005358/primarydocument.xml","form_type":"4"}},{"id":1467539,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":18114,"kind":"person","name":"PARSHALL B LYNNE","position":1,"cik":"0001073385","reported_name":"PARSHALL B LYNNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:02:16.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005357","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1073385/000156218024005357/primarydocument.xml","form_type":"4"}},{"id":1467015,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:00:47.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005356","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000156218024005356/primarydocument.xml","form_type":"4"}},{"id":1501738,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":63978,"kind":"organization","name":"Flagship Pioneering, LLC","position":1,"cik":"0001400240","reported_name":"Flagship Pioneering Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63983,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","position":2,"cik":"0001826217","reported_name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64114,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II, L.P.","position":3,"cik":"0001761283","reported_name":"Flagship Pioneering Special Opportunities Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44731,"kind":"person","name":"Afeyan Noubar","position":4,"cik":"0001222012","reported_name":"AFEYAN NOUBAR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase Common Stock","published_at":"2024-05-24T21:05:08.000Z","date":"2024-05-22","kind":"purchase","planned":false,"acquired":true,"shares":1814915,"price":5.5099,"value":10000000.1585,"ownership":{"direct":false,"nature":"By Flagship Pioneering Fund VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. (\"Flagship Opportunities Fund II\") and Flagship Pioneering Fund VII, L.P. (\"Flagship Fund VII\") acquired pre-funded warrants (the \"Pre-Funded Warrants\") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. (\"Flagship Opportunities Fund II\") and Flagship Pioneering Fund VII, L.P. (\"Flagship Fund VII\") acquired pre-funded warrants (the \"Pre-Funded Warrants\") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. (\"Flagship Opportunities Fund II\") and Flagship Pioneering Fund VII, L.P. (\"Flagship Fund VII\") acquired pre-funded warrants (the \"Pre-Funded Warrants\") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC (\"Flagship Fund VII GP\") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. (\"Flagship Pioneering\") is the manager of Flagship Fund VII GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1814915,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1814915},"source":{"system":"sec-edgar","filing":"0000950170-24-064713","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222012/000095017024064713/ownership.xml","form_type":"4"}},{"id":1501737,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":63978,"kind":"organization","name":"Flagship Pioneering, LLC","position":1,"cik":"0001400240","reported_name":"Flagship Pioneering Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63983,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","position":2,"cik":"0001826217","reported_name":"Flagship Pioneering Special Opportunities Fund II General Partner LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64114,"kind":"organization","name":"Flagship Pioneering Special Opportunities Fund II, L.P.","position":3,"cik":"0001761283","reported_name":"Flagship Pioneering Special Opportunities Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44731,"kind":"person","name":"Afeyan Noubar","position":4,"cik":"0001222012","reported_name":"AFEYAN NOUBAR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase Common Stock","published_at":"2024-05-24T21:05:08.000Z","date":"2024-05-22","kind":"purchase","planned":false,"acquired":true,"shares":1814914,"price":5.5099,"value":9999994.6486,"ownership":{"direct":false,"nature":"By Flagship Pioneering Special Opportunities Fund II, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. (\"Flagship Opportunities Fund II\") and Flagship Pioneering Fund VII, L.P. (\"Flagship Fund VII\") acquired pre-funded warrants (the \"Pre-Funded Warrants\") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. (\"Flagship Opportunities Fund II\") and Flagship Pioneering Fund VII, L.P. (\"Flagship Fund VII\") acquired pre-funded warrants (the \"Pre-Funded Warrants\") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. (\"Flagship Opportunities Fund II\") and Flagship Pioneering Fund VII, L.P. (\"Flagship Fund VII\") acquired pre-funded warrants (the \"Pre-Funded Warrants\") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held by Flagship Opportunities Fund II. Flagship Pioneering Special Opportunities Fund II General Partner LLC (\"Flagship Opportunities Fund II GP\") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. (\"Flagship Pioneering\") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1814914,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1814914},"source":{"system":"sec-edgar","filing":"0000950170-24-064713","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222012/000095017024064713/ownership.xml","form_type":"4"}},{"id":1540136,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":71808,"kind":"person","name":"Humer Kristian","position":1,"cik":"0001872280","reported_name":"Humer Kristian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2024-04-17T16:01:57.000Z","date":"2024-04-16","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":6.03,"value":1658250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on April 16, 2025, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested."}],"balance_after":275000,"derivative":{"exercise_price":6.03,"expiration_date":"2034-04-15","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001562180-24-003439","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872280/000156218024003439/primarydocument.xml","form_type":"4"}},{"id":1579957,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":89580,"kind":"person","name":"Cavalie Fanny","position":1,"cik":"0001913484","reported_name":"Cavalie Fanny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy/Bus Ops Officer"}}],"security":"Common Stock","published_at":"2024-03-12T20:19:27.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":11000,"price":6.5576,"value":72133.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $6.50 USD to $6.83 USD; the price reported above reflects the weighted average sale price."}],"balance_after":75992,"source":{"system":"sec-edgar","filing":"0001562180-24-002591","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024002591/primarydocument.xml","form_type":"4"}},{"id":1670625,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-25T21:05:59.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":3.06,"value":918000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":300000,"derivative":{"exercise_price":3.06,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001562180-24-000611","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024000611/primarydocument.xml","form_type":"4"}},{"id":1670624,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":89580,"kind":"person","name":"Cavalie Fanny","position":1,"cik":"0001913484","reported_name":"Cavalie Fanny","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy/Bus Ops Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-25T21:03:46.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":3.06,"value":244800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":80000,"derivative":{"exercise_price":3.06,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-24-000608","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024000608/primarydocument.xml","form_type":"4"}},{"id":1670623,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68155,"kind":"person","name":"Costa Carlos","position":1,"cik":"0001939167","reported_name":"Costa Carlos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-25T21:03:02.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":3.06,"value":275400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":90000,"derivative":{"exercise_price":3.06,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001562180-24-000607","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024000607/primarydocument.xml","form_type":"4"}},{"id":1670622,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68153,"kind":"person","name":"Bellon Steven F.","position":1,"cik":"0001831749","reported_name":"Bellon Steven F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-25T21:02:33.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":3.06,"value":336600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":110000,"derivative":{"exercise_price":3.06,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001562180-24-000606","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024000606/primarydocument.xml","form_type":"4"}},{"id":1670621,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68154,"kind":"person","name":"LaCascia Michael","position":1,"cik":"0001831755","reported_name":"LaCascia Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-25T21:01:40.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":3.06,"value":306000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":100000,"derivative":{"exercise_price":3.06,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001562180-24-000605","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218024000605/primarydocument.xml","form_type":"4"}},{"id":1670641,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68157,"kind":"person","name":"Cardama Alfonso Quintas","position":1,"cik":"0001760104","reported_name":"Cardama Alfonso Quintas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-25T16:04:15.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":3.06,"value":183600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":60000,"derivative":{"exercise_price":3.06,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001562180-24-000609","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760104/000156218024000609/primarydocument.xml","form_type":"4"}},{"id":1713879,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":16070,"kind":"person","name":"SMITH IAN F","position":1,"cik":"0001197032","reported_name":"SMITH IAN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-12T21:00:39.000Z","date":"2023-12-08","kind":"grant","planned":false,"acquired":true,"shares":26977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to a consulting agreement effective December 8, 2023 (the \"Effective Date\"). The option will vest as to 1/12 of the underlying shares of common stock on the first day of each month beginning on January 1, 2024, with the balance of then-unvested shares to vest one year after the Effective Date."}],"balance_after":26977,"derivative":{"exercise_price":5.63,"expiration_date":"2033-12-07","underlying":"Common Stock","underlying_shares":26977},"source":{"system":"sec-edgar","filing":"0001562180-23-008311","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197032/000156218023008311/primarydocument.xml","form_type":"4"}},{"id":1781706,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":68157,"kind":"person","name":"Cardama Alfonso Quintas","position":1,"cik":"0001760104","reported_name":"Cardama Alfonso Quintas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-09-13T16:01:34.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":272000,"price":7.57,"value":2059040.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on September 11, 2024, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested."}],"balance_after":272000,"derivative":{"exercise_price":7.57,"expiration_date":"2033-09-10","underlying":"Common Stock","underlying_shares":272000},"source":{"system":"sec-edgar","filing":"0001562180-23-006837","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760104/000156218023006837/primarydocument.xml","form_type":"4"}},{"id":1801967,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-08-18T20:03:38.000Z","date":"2023-08-16","kind":"exercise","planned":false,"acquired":false,"shares":311297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 25% of the underlying shares of common stock on September 16, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.72,"expiration_date":"2029-09-16","underlying":"Common Stock","underlying_shares":311297},"source":{"system":"sec-edgar","filing":"0001562180-23-006433","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000156218023006433/primarydocument.xml","form_type":"4"}},{"id":1801966,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-18T20:03:38.000Z","date":"2023-08-16","kind":"sale","planned":false,"acquired":false,"shares":311297,"price":8.25,"value":2568200.25,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-23-006433","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000156218023006433/primarydocument.xml","form_type":"4"}},{"id":1801965,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-18T20:03:38.000Z","date":"2023-08-16","kind":"exercise","planned":false,"acquired":true,"shares":311297,"price":3.72,"value":1158024.84,"ownership":{"direct":true},"balance_after":311297,"source":{"system":"sec-edgar","filing":"0001562180-23-006433","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000156218023006433/primarydocument.xml","form_type":"4"}},{"id":1801451,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-18T20:03:37.000Z","date":"2023-08-17","kind":"gift","planned":false,"acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 17, 2023, the Reporting Person transferred 63,000 shares of the Issuer's Common Stock to the Adrian H. Gottschalk Living Trust dated September 8, 2009. This was a bona fide gift with no payment in consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 300,000 shares held by the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023, of which the Reporting Person is the trustee and sole current beneficiary; 110,690 shares held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, of which the Reporting Person is the trustee and sole current beneficiary; and 101,014 shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee"}],"balance_after":511704,"source":{"system":"sec-edgar","filing":"0001562180-23-006432","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218023006432/primarydocument.xml","form_type":"4"}},{"id":1801450,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-18T20:03:37.000Z","date":"2023-08-17","kind":"gift","planned":false,"acquired":false,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 17, 2023, the Reporting Person transferred 63,000 shares of the Issuer's Common Stock to the Adrian H. Gottschalk Living Trust dated September 8, 2009. This was a bona fide gift with no payment in consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-23-006432","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218023006432/primarydocument.xml","form_type":"4"}},{"id":1846916,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":18114,"kind":"person","name":"PARSHALL B LYNNE","position":1,"cik":"0001073385","reported_name":"PARSHALL B LYNNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:15:14.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005481","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1073385/000156218023005481/primarydocument.xml","form_type":"4"}},{"id":1846449,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":15980,"kind":"person","name":"Lynch Thomas J. Jr.","position":1,"cik":"0001474056","reported_name":"Lynch Thomas J. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:14:53.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005480","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474056/000156218023005480/primarydocument.xml","form_type":"4"}},{"id":1846468,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:14:15.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005479","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218023005479/primarydocument.xml","form_type":"4"}},{"id":1846310,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":16070,"kind":"person","name":"SMITH IAN F","position":1,"cik":"0001197032","reported_name":"SMITH IAN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:13:50.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005478","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197032/000156218023005478/primarydocument.xml","form_type":"4"}},{"id":1846180,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35328,"kind":"person","name":"Biller Scott","position":1,"cik":"0001581956","reported_name":"Biller Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:13:27.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005477","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581956/000156218023005477/primarydocument.xml","form_type":"4"}},{"id":1846182,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:12:08.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005476","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000156218023005476/primarydocument.xml","form_type":"4"}},{"id":1846681,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35426,"kind":"person","name":"GILL SIMBA","position":1,"cik":"0001180763","reported_name":"GILL SIMBA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:11:13.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005475","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180763/000156218023005475/primarydocument.xml","form_type":"4"}},{"id":1846176,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35327,"kind":"person","name":"Mendelsohn Michael","position":1,"cik":"0001591109","reported_name":"Mendelsohn Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:10:35.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005474","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591109/000156218023005474/primarydocument.xml","form_type":"4"}},{"id":1873013,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-01T01:22:55.000Z","date":"2023-05-26","kind":"gift","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 26, 2023, 300,000 shares of the Issuer's Common Stock were transferred from the Adrian H. Gottschalk Living Trust dated September 8, 2009 to the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023. This was a bona fide gift with no payment in consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 300,000 shares held by the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023, of which the Reporting Person is the trustee and sole current beneficiary, 110,690 shares held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, of which the Reporting Person is the trustee and sole current beneficiary, and 38,014 shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee."}],"balance_after":448704,"source":{"system":"sec-edgar","filing":"0001562180-23-004642","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218023004642/primarydocument.xml","form_type":"4"}},{"id":1873012,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-01T01:22:55.000Z","date":"2023-05-26","kind":"gift","planned":false,"acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 26, 2023, 300,000 shares of the Issuer's Common Stock were transferred from the Adrian H. Gottschalk Living Trust dated September 8, 2009 to the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023. This was a bona fide gift with no payment in consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 300,000 shares held by the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust dated May 26, 2023, of which the Reporting Person is the trustee and sole current beneficiary, 110,690 shares held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, of which the Reporting Person is the trustee and sole current beneficiary, and 38,014 shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee."}],"balance_after":448704,"source":{"system":"sec-edgar","filing":"0001562180-23-004642","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218023004642/primarydocument.xml","form_type":"4"}},{"id":1998406,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-22T21:23:01.000Z","date":"2023-02-17","kind":"other","acquired":true,"shares":184939,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Transfer of assets between the the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, and the Adrian H. Gottschalk Living Trust dated September 8, 2009."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Consists of 110,690 shares held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, of which the Reporting Person is the trustee and sole current beneficiary, and 338,014 shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee."}],"balance_after":448704,"source":{"system":"sec-edgar","filing":"0001562180-23-001675","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218023001675/primarydocument.xml","form_type":"4"}},{"id":1998405,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-22T21:23:01.000Z","date":"2023-02-17","kind":"other","acquired":false,"shares":184939,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Transfer of assets between the the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, and the Adrian H. Gottschalk Living Trust dated September 8, 2009."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Consists of 110,690 shares held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, of which the Reporting Person is the trustee and sole current beneficiary, and 338,014 shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee."}],"balance_after":448704,"source":{"system":"sec-edgar","filing":"0001562180-23-001675","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218023001675/primarydocument.xml","form_type":"4"}},{"id":1998404,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-22T21:23:01.000Z","date":"2023-02-17","kind":"gift","acquired":true,"shares":4371,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On February 17, 2023, the Reporting Person transferred 4,371 shares of the Issuer's Common Stock to the Adrian H. Gottschalk Living Trust dated September 8, 2009. This was a bona fide gift with no payment in consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Consists of 295,629 shares held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, of which the Reporting Person is the trustee and sole current beneficiary, and 153,075 shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee."}],"balance_after":448704,"source":{"system":"sec-edgar","filing":"0001562180-23-001675","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218023001675/primarydocument.xml","form_type":"4"}},{"id":1998403,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-22T21:23:01.000Z","date":"2023-02-17","kind":"gift","acquired":false,"shares":4371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On February 17, 2023, the Reporting Person transferred 4,371 shares of the Issuer's Common Stock to the Adrian H. Gottschalk Living Trust dated September 8, 2009. This was a bona fide gift with no payment in consideration."}],"balance_after":63000,"source":{"system":"sec-edgar","filing":"0001562180-23-001675","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218023001675/primarydocument.xml","form_type":"4"}},{"id":1998402,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":52661,"kind":"person","name":"GOTTSCHALK ADRIAN","position":1,"cik":"0001828724","reported_name":"GOTTSCHALK ADRIAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-22T21:23:01.000Z","date":"2022-10-25","kind":"other","acquired":false,"shares":4371,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Reported late due to administrative error."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Transfer of assets between the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, and the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Consists of 295,629 shares held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, of which the Reporting Person is the trustee and sole current beneficiary, and 148,704 shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee."}],"balance_after":444333,"source":{"system":"sec-edgar","filing":"0001562180-23-001675","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1822462/000156218023001675/primarydocument.xml","form_type":"4"}}],"next_cursor":"2023-02-22T21:23:01.000000Z,1998402"}